This trial is active, not recruiting.

Condition hepatocellular carcinoma
Treatment surgical treatment
Sponsor First Affiliated Hospital, Sun Yat-Sen University
Collaborator Guangdong Province, Department of Science and Technology
Start date October 2012
End date October 2013
Trial size 50 participants
Trial identifier NCT01892072, k0113011-2013VEGF


The investigators study the VEGF signaling in HCC cell lines and its mechanism in HCC growth, proliferation and apoptosis.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective
Hepatocellular carcinoma patients treated by surgical treatment
surgical treatment
all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.

Primary Outcomes

the variation of the quantity of VEGF signal pathway genes in normal liver tissue,peri tumor,tumor and metastasis.
time frame: the day when conducting surgery (day 1)

Eligibility Criteria

Male or female participants from 16 years up to 80 years old.

Inclusion Criteria: 1. hepatocellular patients diagnosed through biopsy;or either dynamic imagine with a diagnosis of hepatocellular carcinoma and alphafetoprotein>400μg/L;or two or more dynamic imagine with a diagnosis of hepatocellular carcinoma 2. Child-Pugh A or B 3. well preserved renal and hematopoietic Function 4. receive surgical therapy 5. achieve complete section accessed by contrast-enhanced CT Exclusion Criteria: 1. incomplete section 2. remote metastasis 3. Child-Pugh C 4. combination with other hepatobiliary disease 5. suffer from other tumors concurrently or in last five years

Additional Information

Official title VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway
Principal investigator Ming Kuang, MD
Description Several studies have documented the elevated expression of VEGF, VEGFR1 and VEGFR2 in HCC cell lines and tumor tissues. Another study observed a sequential elevation of VEGF in low-grade dysplasia, high-grade dysplasia and early stage HCC. Clinical analyses have discovered the high expression of VEGF is correlated with tumor progression, vascular invasion, distal metastasis and poor prognosis. However, few studies have been conducted to investigate the VEGF signaling in HCC cells and its possible mechanism in regulating HCC growth.Therefore,we try to clarify the mechanism of VEGF signal in HCC growth,proliferation and apoptosis.
Trial information was received from ClinicalTrials.gov and was last updated in July 2013.
Information provided to ClinicalTrials.gov by First Affiliated Hospital, Sun Yat-Sen University.